Beobachtungsstudie
Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China
Clinical Nephrology · 2026
DOI: 10.5414/cn111956 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Nephrology, 2026. Verfasst von Yi Qian Zhang und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Sodium-Glucose Transporter 2 Inhibitors, Glucosides, Kidney.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Glomerulonephritis, IGASodium-Glucose Transporter 2 InhibitorsGlucosidesKidneyBenzhydryl CompoundsHumansFemaleMaleRetrospective StudiesChinaGlomerular Filtration RateAdultTreatment OutcomeMiddle AgedCreatinineAlbuminuriaUric Acid
Substanzen
Sodium-Glucose Transporter 2 InhibitorsCreatinineUric AcidGlucosidesBenzhydryl Compounds
Zitieren
APA
Zhang, Y. Q., Wu, J. X., Tu, H. Y., Ren, Z. T., Chen, P. P., Zhang, J. X., & Ma, K. L. (2026). Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China. Clinical Nephrology. https://doi.org/10.5414/cn111956
Vancouver
Zhang YQ, Wu JX, Tu HY, Ren ZT, Chen PP, Zhang JX, et al. Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China. Clinical Nephrology. 2026. doi:10.5414/cn111956
BibTeX
@article{Zhang2026,
author = {Zhang, Yi Qian and Wu, Jun Xia and Tu, Hai Yan and Ren, Zhao Ting and Chen, Pei Pei and Zhang, Jia Xiu and Ma, Kun Ling},
title = {Efficacy and safety of henagliflozin in IgA nephropathy: A real-world observational study from China},
journal = {Clinical Nephrology},
year = {2026},
doi = {10.5414/cn111956}
}
EUVIMED